SPOTLIGHT: Novexel licenses anti-fungal drug


Novexel has agreed to license Indevus anti-fungal drug aminocandin for $1.5 million up front, $2.5 million on initiation of mid-level trials and up to $41 million in milestones and royalties. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.